Evidence map›Paper›PMID 34051755›Full record

ArticleBMC bioinformatics2021

Incorporating support vector machine with sequential minimal optimization to identify anticancer peptides.

Yu Wan, Zhuo Wang, Tzong-Yi Lee

Abstract read
In one paragraph

Article in BMC bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yu WanSchool of Life and Health Sciences, The Chinese University of Hong Kong, Shenzhen, Shenzhen, 518172, Guangdong, People's Republic of China.
Zhuo WangWarshel Institute for Computational Biology, The Chinese University of Hong Kong, Shenzhen, Shenzhen, 518172, Guangdong, People's Republic of China.
Tzong-Yi LeeSchool of Life and Health Sciences, The Chinese University of Hong Kong, Shenzhen, Shenzhen, 518172, Guangdong, People's Republic of China. francislee0215@gmail.com.

Funding

National Natural Science Foundation of China 32070659
6 · The paper itself

Abstract

backgroundCancer is one of the major causes of death worldwide. To treat cancer, the use of anticancer peptides (ACPs) has attracted increased attention in recent years. ACPs are a unique group of small molecules that can target and kill cancer cells fast and directly. However, identifying ACPs by wet-lab experiments is time-consuming and labor-intensive. Therefore, it is significant to develop computational tools for ACPs prediction. Though some ACP prediction tools have been developed recently, their performances are not well enough and most of them do not offer a function to distinguish ACPs from antimicrobial peptides (AMPs). Considering the fact that a growing number of studies have shown that some AMPs exhibit anticancer function, this work tries to build a model for distinguishing AMPs from ACPs in addition to a model that predicts ACPs from whole peptides.

resultsThis study chooses amino acid composition, N5C5, k-space, position-specific scoring matrix (PSSM) as features, and analyzes them by machine learning methods, including support vector machine (SVM) and sequential minimal optimization (SMO) to build a model (model 2) for distinguishing ACPs from whole peptides. Another model (model 1) that distinguishes ACPs from AMPs is also developed. Comparing to previous models, models developed in this research show better performance (accuracy: 85.5% for model 1 and 95.2% for model 2).

conclusionsThis work utilizes a new feature, PSSM, which contributes to better performance than other features. In addition to SVM, SMO is used in this research for optimizing SVM and the SMO-optimized models show better performance than non-optimized models. Last but not least, this work provides two different functions, including distinguishing ACPs from AMPs and distinguishing ACPs from all peptides. The second SMO-optimized model, which utilizes PSSM as a feature, performs better than all other existing tools.

Indexed as

Antineoplastic AgentsNeoplasmsHumansMachine LearningPeptidesSupport Vector MachineAntineoplastic AgentsPeptidesAnticancer peptidesPSSMSMOSVM

Identifiers

PMID34051755
PMCPMC8164238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.